Status:
NO_LONGER_AVAILABLE
An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
Lead Sponsor:
Five Prime Therapeutics, Inc.
Conditions:
Recurrent Bladder Cancer
Eligibility:
MALE
18+ years
Brief Summary
This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer
Detailed Description
This protocol is intended to provide access to bemarituzumab (FPA144 an investigational agent) to a single patient with recurrent bladder cancer who had a response to study drug on FPA144-001. That st...
Eligibility Criteria
Inclusion
- Understand and sign an Institutional Review Board-approved informed consent form prior to receiving bemarituzumab
- Previously enrolled on the FPA144-001 study, received bemarituzumab and obtained clinical benefit from the investigational product (IP) administration
Exclusion
- 1\. Pregnancy and lactation
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03801278
Last Update
December 13 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.